【招银国际】 Outperforming FY22E, promising FY23E and not-far-fetching FY25E target.pdf

知乎（ZH US）4Q21E 稳健，FY22E 过渡

Resilient FY22／1H23 despite industry headwinds

Mandi led growth in FY22E, NRDL renewal de-risked

华润医药：1H22业绩巩固了FY22E的正面

石四药集团：强劲的1H22结果；但FY22E指引略低

FY22E preview; Bumpy recovery in 2023

遥望科技(002291)FY22&1Q23业绩交流会-调研纪要

Yanlord：Resilient FY22 results and business model; maintain Buy

Hopson： weaker but much better than peers FY22

FY22 largely in-line; Auto／VR to accelerate growth